Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

26 search results for igg

filterselect all | reset

Sort by

Order

Suggestions within Pfizer.com

Announcement

Article

Page

People Profiles

Podcast

Press Release

Product

filter select all | reset

Type

Announcement

Article

Page

People Profiles

Podcast

Press Release

Product

Date Range

Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases

ordered multimers of normal human IgG Fc to its receptors. About Gliknik …

Press Release
Science Fact or Science Fiction? Avoiding Peanuts as an Infant Reduces Allergy Risk

encounters that allergen again, it triggers an inflammatory response. "It protective immunoglobulins known as IgG and IgG4. "The LEAP study was a …

Article
BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2

as measured by RBD-binding IgG concentrations and SARS-CoV-2 …

Press Release
FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions

Hypogammaglobulinemia (IgA, IgG, or IgM below the lower limit of levels at baseline had low IgA, IgG, and IgM levels, respectively, …

Press Release
Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARSCoV-2 in Nature

as measured by RBD-binding IgG concentrations and SARS-CoV-2 …

Press Release
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

(NI) of immunoglobin G (IgG) geometric mean concentrations with predefined serotype-specific IgG concentrations after Dose 3 (two …

Press Release
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)

antibodies called “immunoglobulins” (IgG) in the blood which help protect …

Press Release
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

titers and RBD-binding IgG concentrations after the second …

Press Release
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2

adults, which suggest that BNT162b2 triggers the production of neutralizing receptor binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 …

Press Release
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS

adults, which suggest that BNT162b2 triggers the production of neutralizing with prespecified serotype-specific IgG concentrations and IgG Geometric …

Press Release

Page 1
Current page 2
Page 3

Home
News
Press Releases

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

April 2025

04.16.2025
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
- Vaccines
- Vaccines
04.14.2025
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
- Research and Pipeline
- Research
04.10.2025
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
- Corporate
- Finance
04.01.2025
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
- Vaccines
- Vaccines

March 2025

03.18.2025
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
- Financial
- Finance
03.11.2025
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
- Research and Pipeline
- Research

February 2025

02.24.2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance
02.13.2025
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
- Prescription Medicines
- Medicines
02.12.2025
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Prescription Medicines
- Medicines
02.10.2025
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
- Research and Pipeline
- Medicines
02.04.2025
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
02.03.2025
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
- Prescription Medicines
- Medicines

January 2025

01.28.2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
- Research and Pipeline
01.25.2025
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
01.10.2025
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Research and Pipeline
- Research
01.06.2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance

December 2024

12.20.2024
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
- Prescription Medicines
- Medicines
12.19.2024
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
- Financial
- Finance
12.17.2024
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
12.12.2024
Pfizer Declares First-Quarter 2025 Dividend
- Financial
- Finance
12.12.2024
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- Prescription Medicines
- Medicines
12.10.2024
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
- Financial
- Finance
12.10.2024
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
12.05.2024
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
- Research

November 2024

11.20.2024
Pfizer Announces New Chief Scientific Officer and President, Research & Development
- Corporate
- Leadership
11.20.2024
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
- Prescription Medicines
- Medicines
11.14.2024
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance
11.04.2024
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance

October 2024

10.29.2024
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
10.23.2024
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
- Vaccines
- Vaccines
10.22.2024
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
- Vaccines
- Vaccines
10.22.2024
Pfizer Supplies One Billionth Pneumococcal Conjugated Vaccine Dose for Vaccination of Children in Lower- Income Countries Through Gavi, the Vaccine Alliance
- Corporate
- Partnerships
10.15.2024
Tim Buckley Elected to Pfizer’s Board of Directors
- Corporate
- Leadership
10.11.2024
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
- Prescription Medicines
- Medicines
10.10.2024
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
- Prescription Medicines
- Medicines
10.09.2024
Pfizer Declares Fourth-Quarter 2024 Dividend
- Financial
- Finance
10.08.2024
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

September 2024

09.25.2024
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
- Prescription Medicines
- Medicines
09.20.2024
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- Vaccines
- Vaccines
09.17.2024
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
- Financial
- Finance
09.14.2024
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
- Research and Pipeline
- Research
09.14.2024
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
- Prescription Medicines
- Research
09.11.2024
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
- Research and Pipeline
- Research
09.03.2024
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
- Corporate
- Partnerships

August 2024

08.28.2024
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- Financial
- Finance
08.27.2024
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
08.22.2024
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- Vaccines
- Vaccines
08.16.2024
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Page 1
Current page 2
Page 3
Page 4
Page 5

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

PfizerForAll
Healthcare Professionals
Grant Seekers
Business to Business

Privacy Statement
Accessibility Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube